Cross-Sector entity
American Medical Association (AMA) is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in pharma, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 3 original sources on average.
2 verified stories tracked
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
American Medical Association (AMA) is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in pharma, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 3 original sources on average. We currently track 2 Cross-Sector stories that mention Pharmaceutical Research and Manufacturers of America (PhRMA), all published on March 9, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pharmaceutical Research and Manufacturers of America (PhRMA). Shared-story counts are live from our verified record — not editorial picks.
The pharmaceutical industry faces renewed scrutiny over direct-to-consumer (DTC) advertising, a practice unique to the U.S. and New Zealand. As healthcare costs rise, regulators are weighing the educational benefits of these ads against their role in driving up prescription volumes and drug prices.
A renewed public debate over Direct-to-Consumer Advertising (DTCA) is challenging the pharmaceutical industry's marketing status quo in the United States. As healthcare costs escalate, regulators and lawmakers are weighing the educational benefits of patient outreach against the risks of over-prescription and inflated drug prices.
